White Ginseng Extract (Panax ginseng): Standardized Ginsenosides Rb1 & Rg1 — B2B Wholesale Supplier
White ginseng extract preserves the native ginsenoside profile of Panax ginseng C.A. Meyer root through air-drying without heat processing — retaining the full-spectrum Rb1 and Rg1 content that is the focus of most published research on ginseng’s adaptogenic, cognitive, and immune-related activity. Valeherb supplies white ginseng extract in five B2B specifications: 10% total ginsenosides, 30% total ginsenosides, 80% total ginsenosides, 10:1 concentrate, and 20:1 concentrate — covering formulation requirements from functional food to high-purity nutraceutical and pharmaceutical-use manufacturing.
Active Compounds: Why the Native Ginsenoside Profile Matters
White ginseng retains the naturally occurring balance of ginsenosides as they exist in the fresh root. The two dominant and most extensively researched compounds are:
| Ginsenoside | Class | Primary Activity Studied in Research |
|---|---|---|
| Rb1 | Protopanaxadiol (PPD) | Neuroprotective activity via Nrf2 antioxidant pathway; memory consolidation; anti-fatigue; calming CNS modulation[3] |
| Rg1 | Protopanaxatriol (PPT) | Cognitive support; HPA axis stress modulation; inflammatory-pathway signaling (Nrf2/HO-1)[2] |
Rb1 and Rg1 together account for the majority of white ginseng’s researched compound profile. Their complementary mechanisms — Rb1 associated with calming neuroprotection, Rg1 with stimulatory cognitive support — produce the balanced adaptogenic effect that has informed ginseng’s traditional and research use over decades.[3]
Research-Documented Activity Areas
1. Memory & Cognitive Support
A 2024 systematic review and meta-analysis by Zeng et al. covering 15 RCTs and 671 participants reported a statistically significant improvement in memory outcomes with ginseng supplementation (SMD = 0.19, 95% CI: 0.02–0.36, p < 0.05), with stronger effects at higher doses (SMD = 0.33 at high dose).[1] Memory is the most consistently supported cognitive endpoint across the ginseng clinical literature, which makes it the most defensible basis for a structure/function claim — though any finished-product claim remains the marketer’s responsibility to substantiate.
2. Adaptogenic Stress Modulation
Ginsenosides Rb1 and Rg1 have been studied for interaction with glucocorticoid receptors and modulation of HPA axis activity — a core mechanism associated with adaptogenic stress protection. Preclinical research indicates both compounds activate Nrf2-mediated antioxidant defense, protecting neuronal cells from oxidative stress-induced damage.[3][4] In research, this mechanism is associated with physical recovery, fatigue reduction, and stress resilience — without the stimulant profile of caffeine-based alternatives.
3. Inflammatory-Pathway & Immune Research
Rg1 has been studied for inflammatory-pathway activity via Nrf2/HO-1 signaling, including effects on pro-inflammatory cytokine expression.[2] Combined with Rb1’s antioxidant activity, these are research areas relevant to immune-support and seasonal-wellness formulation categories.
Available Specifications
| Specification | Ginsenoside Content | Recommended Application |
|---|---|---|
| 10% Total Ginsenosides | 10% by HPLC | General wellness supplements, functional foods, entry-level capsules and tablets, herbal blends where a standard supplement-grade marker is specified |
| 30% Total Ginsenosides | 30% by HPLC | Premium supplement capsules, nootropic stacks, functional beverage fortification |
| 80% Total Ginsenosides | 80% by HPLC | High-purity supplement and pharmaceutical-use formulations, low-excipient capsules, cosmeceutical actives |
| 10:1 Concentrate | Standardized concentration ratio; HPLC fingerprint available | General wellness supplements, functional foods, formulations specifying a traditional extract ratio |
| 20:1 Concentrate | Standardized concentration ratio; HPLC fingerprint available | High-concentration capsules, cost-effective delivery of higher ginsenoside load per serving |
Sourcing Criteria: What to Require from Any Supplier
| Criterion | What to Require |
|---|---|
| Ginsenoside Standardization | HPLC-verified total ginsenoside content per batch — not UV spectrophotometry, which cannot distinguish individual ginsenosides |
| Rb1 / Rg1 Breakdown | Individual quantification of Rb1 and Rg1 for premium applications — confirms native white ginseng profile and rules out adulteration or misrepresentation |
| Processing Verification | Air-dried without steaming — request processing documentation confirming white ginseng specification. Rg3 presence on COA is a red flag for mislabeled red ginseng |
| Root Origin & Age | Korean 6-year root is the most clinically validated source. Request origin documentation and root age certification |
| Third-Party COA | Total ginsenosides (HPLC), heavy metals (USP <232>), pesticide residues, microbial limits (USP <2021>), moisture — per batch |
| Certifications | Non-GMO, Kosher/Halal for relevant markets. FDA-registered facility required for US supplement supply chains |
Regulatory Guidance
- US (DSHEA): Any structure/function claim on the finished product is the marketer’s responsibility to substantiate and must carry the FDA disclaimer; memory/cognitive support is the most strongly backed by published RCT and meta-analysis data. Disease treatment claims require drug (NDA) approval
- EU: Panax ginseng root has a well-established use monograph under EMA/HMPC/321232/2012 supporting claims of temporary relief of stress symptoms and fatigue
- Canada (NHPs): Licensed Health Canada monograph supporting cognitive function, physical performance, and immune support claims
References
[1] Zeng M et al. (2024). Effects of ginseng on cognitive function: a systematic review and meta-analysis. Phytotherapy Research, 38(12), 6023–6034. PMID: 39474788
[2] Liang HY et al. (2021). Preclinical systematic review of ginsenoside Rg1 for cognitive impairment in Alzheimer’s disease. Aging, 13(5), 7769–7790. PMID: 33686024
[3] Fernández-Moriano C et al. (2017). Evaluation of the adaptogenic potential exerted by ginsenosides Rb1 and Rg1 against oxidative stress-mediated neurotoxicity in an in vitro neuronal model. PLOS ONE, 12(8), e0182933. PMID: 28813475
[4] Panossian A & Wikman G. (2010). Effects of adaptogens on the central nervous system and molecular mechanisms associated with their stress-protective activity. Pharmaceuticals, 3(1), 188–224. PMID: 27713248





